A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients With Duchenne Muscular Dystrophy
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2018
At a glance
- Drugs WVE 210201 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man
- Sponsors WaVe life Sciences
- 09 Aug 2018 According to a WaVe life Sciences media release, this trial continues to progress through the planned dose escalation with no safety signals observed in the trial.The company now expects to announce safety data from the phase 1 trial by the end of the fourth quarter of 2018.
- 03 May 2018 New source identified and integrated (European Clinical Trials Database; EudraCT2017-002686-21).
- 12 Mar 2018 According to a WaVe life Sciences media release, Safety data from the trial are anticipated in Q3 2018 and expected to facilitate the rapid transition to an open-label extension study and efficacy study.